Interview with Francisco Piccolo, President, Biogen Idec Brazil
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
Address: Av. Doutor Cardoso de Melo, 1.184, 17º andar Vila Olimpia São Paulo – SP – Brasil Cep: 04548-004,Brazil
Tel: +55 11 3568-3400
Web: http://www.biogenidec.com.br/
Biogen Idec Inc. (NASDAQ: BIIB) is a global biotechnology leader with products in oncology, neurology and immunology. Biogen Idec is committed to transforming scientific discoveries into advances and health care. The company’s include the discovery, research, development and biomanufacturing of medicine and a global commercial infrastructure.
Biogen Idec pursues the creativity of science with passion and discipline. For over 25 years, the company has grown through the discovery, development and commercialization of innovative products themselves and through strategic alliances.
Scientific excellence that achieves new standards of care drives the company’s work. Currently, more than twenty products are in clinical development to meet a number of important medical needs.
Biogen Idec has affiliates in Brazil, Canada, Australia, Japan and throughout Europe, including the international headquarters in Zug, Switzerland. The company currently employs approximately 3,600 people worldwide.
In Brazil, Biogen Idec is focused on the Multiple Sclerosis market, as an expert company in the disease, and is responsible for organizing World MS Day activities in the country.
Avonex, Tysabri
When we spoke with Mr. Barbano at ANVISA, he mentioned RDC 55/10 and his hopes that it will do for the biologics market what the generics law of 1999 did…
After international tenures in Korea and at Servier’s global headquarters in Paris, Matthieu Mendil has taken the helm of Servier Brazil at a pivotal moment in the affiliate’s evolution. Drawing…
Rogerio Frabetti, General Manager of Biogen Brazil discusses the organisation’s strategic transformation as it expands beyond its neuroscience heritage into immunology whilst maintaining leadership in rare diseases. He articulates Brazil’s…
Rolf Hoenger discusses Roche LATAM’s growth, emphasising patient-centric strategies, untapped access potential, and evidence-based dialogue with policymakers. He highlights accelerated regulatory approvals, digital health initiatives, and Movement Health Foundation projects,…
Roberto Alvarenga, VP at Biotronik’s Latin American operations, reflects on the company’s six decades of innovation and LatAm’s emergence as the firm’s fastest-growing region. He outlines a strategy focused on…
Vaccination remains the most powerful public health intervention ever devised, preventing an estimated 4.4 million deaths each year, according to the WHO. Yet with misinformation spreading faster than science, and…
Adium is one of Latin America’s most expansive pharmaceutical groups, operating across 18 countries with a workforce of 7,000 employees. The organisation has unified its brand identity across the region…
Sylvester Feddes, Country President of Novartis Brazil, outlines the country’s rise as a top global market driven by strong public-private healthcare infrastructure and vast unmet needs. With nearly 100 active…
Sinan Atlig reflects on a 25-year global career spanning Turkey, Colombia, the Middle East, and the US, shaped decisively by vaccine leadership through the COVID-19 era. He identifies vaccines and…
As one of Brazil’s leading pharmaceutical powerhouses, CIMED has redefined what it means to be both national and innovative. Built on a fully verticalised model that spans from R&D to…
Dr Jarbas Barbosa, Director of the Pan American Health Organization (PAHO), discusses the organisation’s evolution from pandemic response to comprehensive health system transformation, regional production capabilities, and the imperative for…
As Latin America’s largest pharma market, worth USD 62 billion in 2024, Brazil is retooling its industry to meet new demands. Driven by changing demographics, chronic disease burdens, and the…
Brazil’s pharmaceutical sector is undergoing a quiet but significant transformation. Once dominated by multinationals and focused largely on generics, a group of leading domestic players is now charting a different…
See our Cookie Privacy Policy Here
